-

Lowenstein’s Securities Litigation Group Defeats Motion to Dismiss Securities Fraud Opt-Out Suits Against Akorn, Inc.

NEW YORK--(BUSINESS WIRE)--The U.S. District Court for the Northern District of Illinois denied defendant Akorn, Inc.’s motion to dismiss two securities fraud lawsuits brought by several investment funds represented by Lowenstein Sandler’s Securities Litigation Group, ruling that the funds’ claims can proceed against Akorn and its officers and directors because the complaints plausibly allege material misrepresentations and omissions concerning the company’s regulatory noncompliance, which led to the failure of Akorn’s $4.3 billion proposed acquisition by Fresenius Kabi AG and massive investor losses.

In 2017, Akorn, Inc., an American generic pharmaceutical manufacturer, announced that it was being acquired by Fresenius, an international health care company. A whistleblower allegedly alerted Fresenius to possible regulatory compliance issues at Akorn, starting a chain of events that ultimately led to a Delaware court ruling that Fresenius had the right to terminate the merger. Investors, including Lowenstein’s clients, suffered significant losses when the price of Akorn stock plummeted as information about Akorn’s regulatory violations was publicly disclosed. The funds have brought securities fraud actions, alleging that Akorn and its directors and officers made fraudulent misrepresentations that, among other things, violated the Securities Exchange Act of 1934.

In Twin Master Fund Ltd. et al. v. Akorn Inc. et al., and Manikay Master Fund LP et al. v. Akorn Inc. et al., U.S. District Judge Matthew F. Kennelly rejected the defendants’ motions to dismiss the investment funds’ claims, finding that the complaints had pled with particularity that Akorn made false and misleading statements in its SEC filings and communications with the market and had failed to disclose critical information to investors about Akorn’s regulatory noncompliance. Judge Kennelly also ruled that the complaints pled that the investors’ losses were connected to the revelation of Akorn’s fraud–revelations that included Fresenius’s statements regarding the cancellation of the merger.

"It is important that investment managers be allowed to hold those who violate the securities laws accountable," said Lawrence M. Rolnick, Chair of Lowenstein’s Securities Litigation group. “As we did recently in the securities fraud action against VEREIT, Inc., we have been able to provide vigorous prosecution for our clients.”

The Lowenstein team includes Lawrence M. Rolnick, Michael J. Hampson, Richard A. Bodnar, and Jennifer A. Randolph.

Contacts

Lowenstein Sandler
Stephen Kimmerling
skimmerling@lowenstein.com

Lowenstein Sandler


Release Versions

Contacts

Lowenstein Sandler
Stephen Kimmerling
skimmerling@lowenstein.com

More News From Lowenstein Sandler

Life Sciences Leaders Optimistic About Funding Prospects but Cautious About Growth Outlook, New Research Finds

NEW YORK--(BUSINESS WIRE)--Lowenstein Sandler announced today the release of Funding Life Sciences: Where the Opportunities and Resources Are in 2021 and Beyond, a report based on survey results that gauge the sentiment of executives at life sciences startups and early-stage companies regarding the current state of investment in the sector. Coauthored by Michael J. Lerner, partner and Chair, Life Sciences Group, and Steven M. Skolnick, partner and Chair, Capital Markets and Securities Practice,...

Lowenstein Further Expands D.C. Presence and White Collar Practice With Addition of Mark E. Schamel as Partner

NEW YORK--(BUSINESS WIRE)--Lowenstein Sandler is pleased to announce that Mark E. Schamel has joined the firm as partner in the White Collar Criminal Defense group. He will be based in the firm’s rapidly growing Washington, D.C., office. Schamel has over 20 years of experience trying criminal cases in state and federal courts and handling matters in over 30 states across the country. He has represented companies and individuals in some of the largest fraud cases in history, as well as a range o...

Thomas E. Redburn Jr. Named Firmwide Chair of Lowenstein Sandler’s Securities Litigation Practice

NEW YORK--(BUSINESS WIRE)--Thomas E. Redburn Jr. Named Firmwide Chair of Lowenstein Sandler’s Securities Litigation Practice....
Back to Newsroom